Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYN 001 - Synergys

Next Previous
X
Search
Drug Profile

SYN 001 - Synergys

Alternative Names: SYN-001- Synergys Biotherapeutics; SYN001; αEGFR IgG1-huEndo-P125A; αEGFR-E-P125A

Latest Information Update: 03 Apr 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synergys Biotherapeutics; University of Miami
  • Developer Synergys Biotherapeutics
  • Class Antineoplastics; Immunoconjugates; Peptide drug conjugates; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Triple negative breast cancer

Most Recent Events

  • 06 Dec 2022 Preclinical trials in Triple-negative-breast-cancer in USA (Parenteral), prior to December 2022
  • 06 Dec 2022 Pharmacodynamics data from a preclinical trial in Triple negative breast cancer presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS-2022)
  • 10 Oct 2022 Synergys Biotherapeutics anticipates filing of IND application for Breast cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top